bivalent influenza modRNA vaccine (bIRV) / Pfizer - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza (clinicaltrials.gov) - P2 | N=1019 | Completed | Sponsor: BioNTech SE | Phase classification: P1/2 ➔ P2

Phase classification • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza (clinicaltrials.gov) - P1/2 | N=1019 | Completed | Sponsor: BioNTech SE | Phase classification: P2 ➔ P1/2

Phase classification • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza (clinicaltrials.gov) - P2 | N=1018 | Completed | Sponsor: BioNTech SE | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza (clinicaltrials.gov) - P2 | N=1018 | Active, not recruiting | Sponsor: BioNTech SE | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Dec 2023 | Trial primary completion date: Dec 2024 ➔ Dec 2023

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza (clinicaltrials.gov) - P2 | N=990 | Recruiting | Sponsor: BioNTech SE | Phase classification: P1 ➔ P2 | N=180 ➔ 990

Enrollment change • Phase classification • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza (clinicaltrials.gov) - P1/2 | N=1168 | Completed | Sponsor: Pfizer | Recruiting ➔ Completed | N=1980 ➔ 1168 | Trial completion date: Jul 2023 ➔ Jan 2023 | Trial primary completion date: Jul 2023 ➔ Jan 2023

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza (clinicaltrials.gov) - P1/2 | N=1980 | Recruiting | Sponsor: Pfizer | N=615 ➔ 1980

Enrollment change • Infectious Disease • Influenza • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza (clinicaltrials.gov) - P1/2 | N=615 | Recruiting | Sponsor: Pfizer | N=1980 ➔ 615 | Trial completion date: Apr 2023 ➔ Jul 2023 | Trial primary completion date: Apr 2023 ➔ Jul 2023

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza (clinicaltrials.gov) - P1/2 | N=1980 | Recruiting | Sponsor: Pfizer | Phase classification: P2 ➔ P1/2 | N=615 ➔ 1980 | Trial completion date: Jan 2023 ➔ Apr 2023 | Trial primary completion date: Jan 2023 ➔ Apr 2023

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza (clinicaltrials.gov) - P2 | N=615 | Recruiting | Sponsor: Pfizer | Phase classification: P1/2 ➔ P2

Phase classification • Infectious Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza (clinicaltrials.gov) - P1/2 | N=615 | Recruiting | Sponsor: Pfizer | N=1065 ➔ 615

Enrollment change • Infectious Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza (clinicaltrials.gov) - P1/2 | N=1065 | Recruiting | Sponsor: Pfizer | Phase classification: P1 ➔ P1/2 | N=615 ➔ 1065

Enrollment change • Phase classification • Infectious Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza (clinicaltrials.gov) - P1; N=615; Recruiting; Sponsor: Pfizer; Trial completion date: Jul 2022 ➔ Nov 2022; Trial primary completion date: Jul 2022 ➔ Nov 2022

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza (clinicaltrials.gov) - P1; N=615; Recruiting; Sponsor: Pfizer; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Respiratory Diseases